For pediatric patients with inflammatory bowel disease (IBD), a booster dose of pertussis vaccine was safe and immunogenic. Findings from the study are published in Inflammatory Bowel Diseases.
A team of Polish researchers conducted a multicenter, prospective, controlled trial that included 138 patients aged 11–18 years with no history of pertussis booster immunization after age 6 or history of pertussis. They aimed to compare the immunogenicity among pediatric patients with IBD vs. healthy controls.
Study patients were grouped into 1 of the following: patients with IBD receiving no immunosuppressive therapy (Group 1), those on thiopurines only (Group 2), those on thiopurines and TNF-α agents (Group 3), and healthy controls (Group 4). The control group and patients were given 1 dose of pertussis vaccine via intramuscular injection and were asked to record adverse effects for 3 days post-vaccination.
The study’s primary outcome measure was adequate vaccine response, defined as the concentration of anti-Bordetella pertussis antibodies >11mcg/mL assessed between 4–8 weeks post-vaccination.
The data showed no difference in the rates of adequate vaccine response between the 4 study groups (P=0.11). Patients with IBD taking immunosuppressive therapy did not differ from those not taking immunosuppressive therapy (90.6% vs. 88.2%;P=0.37). Moreover, there were no serious adverse effects related to vaccine administration.
For more information visit ovid.com.